FAM
JBIO

Fred Alger Management’s Jade Biosciences JBIO Stock Holding History

Fred Alger Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,251
Closed -$1.29M – 432
2024
Q1 		$1.29M Buy
1,251
+209
+20% +$160K 0.01% 362
2023
Q4 		$825K Buy
1,042
+335
+47% +$171K ﹤0.01% 374
2023
Q3 		$336K Sell
707
-947
-57% -$513K ﹤0.01% 394
2023
Q2 		$993K Sell
1,654
-1,319
-44% -$844K 0.01% 379
2023
Q1 		$2.1M Sell
2,973
-1,254
-30% -$1.04M 0.01% 342
2022
Q4 		$4.34M Sell
4,227
-981
-19% -$712K 0.02% 276
2022
Q3 		$3.02M Buy
5,208
+274
+6% +$183K 0.02% 300
2022
Q2 		$2.7M Buy
4,934
+162
+3% +$77.4K 0.01% 319
2022
Q1 		$3.06M Hold
4,772
– – 0.01% 312
2021
Q4 		$1.97M Buy
+4,772
New +$2.41M ﹤0.01% 356

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fred Alger Management's JBIO Position: Q2 2024 in Review

Fred Alger Management sold out of Jade Biosciences (JBIO) in Q2 2024, closing a stake of 1,251 shares — an estimated $1.29M sold.

Fred Alger Management first reported a position in JBIO in Q4 2021 and held it in 10 quarters. The position peaked at $4.34M in Q4 2022. 80 funds tracked by Wall St. Rank hold JBIO as of Q2 2024.

  • Fred Alger Management reported no remaining Jade Biosciences position as of Q2 2024 after selling out during the quarter.
  • Fred Alger Management sold 1,251 Jade Biosciences shares in Q2 2024, an estimated $1.29M.
  • Fred Alger Management first reported a position in Jade Biosciences in Q4 2021 and held it in 10 quarters.
  • Fred Alger Management's Jade Biosciences position peaked at $4.34M in Q4 2022.
  • 80 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2024.

Based on Fred Alger Management's 13F filing for Q2 2024, filed 14 Aug 2024.